Article2018-02-06T17:27:34+00:00

PHE's Snider Presents New CAR T-cell Study at ASCO: CAR T-cell Therapy Benefit Dependent on Prompt Treatment

At the ASCO Annual Meeting in Chicago, PHE Senior Director, Policy & Economics Julia Thornton-Snider, PhD presented a recently-completed study on the impact of treatment delays for patients with pediatric leukemia.

In the study, Dr. Snider and colleagues quantified the social value of tisagenlecleucel (Kymriah) and the value lost from treatment delays, establishing that delays significantly decreased value derived from treatment with tisagenlecleucel among pediatric patients with acute lymphoblastic leukemia.

To read more about the study and/or Dr. Snider’s presentation at ASCO, please click below for recent media coverage of her research and the presentation, as well as the study abstract:

HemOnc Today – Highlights from the ASCO Annual Meeting

Journal of Clinical Pathways

Abstract: The social value of tisagenlecleucel, a CAR-T cell therapy, for the treatment of relapsed or refractory pediatric acute lymphoblastic leukemia in the United States: What are consequences of treatment delays?

Precision Medicine Group is an integrated team of experts in fields from advanced lab sciences to translational informatics and regulatory affairs, payer insights to marketing communications. Together, we help our pharmaceutical and life-sciences clients conquer product development and commercialization challenges in a rapidly evolving environment.

By continuing to use our website, you agree to our use of cookies to help us give you the best experience, analyze your site usage, and assist in our marketing efforts.
For more information, or to learn how to change your cookies preferences, please click here.

OK